RNAi still sizzling: Arrowhead seeks $104.2M for HBV drug
By Marie Powers
Thursday, February 20, 2014
Signaling the RNAi space remains a hot ticket, Arrowhead Research Corp. priced an underwritten offering of 5.5 million shares of common stock at $18.95 apiece, seeking to raise $104.225 million. The Pasadena, Calif.-based company granted the underwriters a 30-day option to purchase up to an additional 825,000 shares, potentially increasing the deal size by $15.6 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.